Evidence map›Paper›PMID 26241824›Full record

ArticlePlasmid2015

Construction and evaluation of an adenoviral vector for the liver-specific expression of the serine/arginine-rich splicing factor, SRSF3.

Amanda L Suchanek, Lisa M Salati

Open access · greenAbstract read
In one paragraph

Article in Plasmid, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amanda L SuchanekDepartment of Biochemistry, West Virginia University School of Medicine, Morgantown, WV 26506, United States.
Lisa M SalatiDepartment of Biochemistry, West Virginia University School of Medicine, Morgantown, WV 26506, United States. Electronic address: Lsalati@hsc.wvu.edu.
West Virginia University · US

Funding

REGULATION OF GENE EXPRESSION BY DIETARY FATR01DK046897 · NIDDK · WEST VIRGINIA UNIVERSITY · PI SALATI, LISA M · 1999 to 2012
$2.8M
Regulation of Gene Expression by Dietary FatR56DK046897 · NIDDK · WEST VIRGINIA UNIVERSITY · PI SALATI, LISA M · 2008 to 2008
$273k
REGULATION OF GENE EXPRESSION BY DIETARY FATR29DK046897 · NIDDK · WEST VIRGINIA UNIVERSITY · PI SALATI, LISA M · 1993 to 1997
–
NIDDK NIH HHS DK46897NIDDK NIH HHS R01 DK046897NIDDK NIH HHS R56 DK046897
6 · The paper itself

Abstract

Serine/arginine-rich splicing factor-3 (SRSF3), alternatively known as SRp20, is a member of the highly-conserved SR protein family of mRNA splicing factors. SRSF3 generally functions as an enhancer of mRNA splicing by binding to transcripts in a sequence-specific manner to both recruit and stabilize the binding of spliceosomal components to the mRNA. In liver, expression of SRSF3 is relatively low and its activity is increased in response to insulin and feeding a high carbohydrate diet. We sought to over-express SRSF3 in primary rat hepatocytes to identify regulatory targets. A standard adenoviral shuttle vector system containing an epitope-tagged SRSF3 under the transcriptional control of the CMV promoter could not be used to produce infectious adenoviral particles. SRSF3 over-expression in the packaging cell line prevented the production of infectious adenovirus particles by interfering with the viral splicing program. To circumvent this issue, SRSF3 expression from the shuttle vector was blocked by placing its expression under the control of the liver-specific albumin promoter. In this system, the FLAG-SRSF3 transgene is only expressed in the target cells (hepatocytes) but not in the packaging cell line. An additional benefit of the albumin promoter is that expression of the transgene does not require the addition of hormones or antibiotics to drive SRSF3 expression in the hepatocytes. Robust expression of FLAG-SRSF3 protein is detected in both HepG2 cells and primary rat hepatocytes infected with adenovirus prepared from this new shuttle vector. Furthermore, abundances of several known and suspected mRNA targets of SRSF3 action are increased in response to over-expression using this virus. This report details the construction of the albumin promoter-driven adenoviral shuttle vector, termed pmAlbAd5-FLAG.SRSF3, that can be used to generate functional adenovirus to express FLAG-SRSF3 specifically in liver. This vector would be suitable for over-expression of other splicing factors that could inhibit virus production. In addition, this vector would allow only liver-specific expression of other cargo genes when used in a whole-animal paradigm.

Indexed as

AdenoviridaeAlbuminsAnimalsCell Line, TumorGene Expression RegulationGenetic VectorsGlucuronidaseHEK293 CellsHepatocytesHep G2 CellsHumansLiverMaleNF-kappa BPlasmidsPromoter Regions, GeneticAlbuminsGlucuronidaseNF-kappa BRNA-Binding ProteinsRNA, MessengerSerine-Arginine Splicing FactorsSRSF3 protein, humanAdenovirusHepatocytesLiverLiver-specific over-expressionmRNA splicingSRSF3

Identifiers

PMID26241824
PMCPMC4648679
OpenAlexW1111728705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.